Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.14 EUR
Change Today +0.005 / 0.23%
Volume 0.0
YDO On Other Exchanges
Symbol
Exchange
Stuttgart
As of 2:17 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

synta pharmaceuticals corp (YDO) Snapshot

Open
€2.18
Previous Close
€2.13
Day High
€2.18
Day Low
€2.14
52 Week High
07/7/14 - €3.64
52 Week Low
03/31/15 - €1.59
Market Cap
287.7M
Average Volume 10 Days
3.9K
EPS TTM
--
Shares Outstanding
134.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNTA PHARMACEUTICALS CORP (YDO)

synta pharmaceuticals corp (YDO) Related Businessweek News

No Related Businessweek News Found

synta pharmaceuticals corp (YDO) Details

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma. The company’s product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; Elesclomol, a mitochondria-targeting agent that is in Phase II clinical trial for ovarian cancer; and CRACM ion channel inhibitors and IL-12/23 inhibitors for the treatment of inflammatory diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.

110 Employees
Last Reported Date: 03/12/15
Founded in 2000

synta pharmaceuticals corp (YDO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $563.3K
Executive Chairman, Chairman of Nominating & ...
Total Annual Compensation: --
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $21.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $77.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $530.3K
Compensation as of Fiscal Year 2014.

synta pharmaceuticals corp (YDO) Key Developments

Synta Pharmaceuticals Corp. Announces Executive Changes

On April 22, 2015, Anne Whitaker notified the Board of Directors of Synta Pharmaceutical Corp. that she was resigning as Synta's President and Chief Executive Officer and as a member of Synta's Board of Directors, effective as of May 7, 2015. In connection with Ms. Whitaker's resignation, on April 23, 2015, the Board of Directors appointed Chen Schor, Synta's current Executive Vice President and Chief Operating Officer, as President and Chief Executive Officer, to be effective as of May 7, 2015 and appointed Mr. Schor as a Class I director with a term expiring at the annual meeting of stockholders to be held in 2017, to be effective as of May 7, 2015, to fill the vacancy to be created by Anne Whitaker's resignation. Mr. Schor joined Synta as Executive Vice President and Chief Operating Officer in December 2014. Mr. Schor has over 15 years of leadership experience in biotechnology, medical devices, business development and private equity. Mr. Schor served as Vice President, Global Branded Products Business Development and Pipeline Management at Teva Pharmaceuticals and in leadership positions at several emerging private and public companies. During his career, Mr. Schor has led licensing and M&A transactions valued at over $8 billion with partners that include GSK, Amgen, Pfizer, Merck KGaA and OncoGeneX, among others.

Synta Pharmaceuticals Corp. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 10:30 AM

Synta Pharmaceuticals Corp. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 10:30 AM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

Synta Pharmaceuticals Corp. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides 2015 Financial Guidance

Synta Pharmaceuticals Corp. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported a net loss of $20,352,000 or $0.19 per basic and diluted share compared to $24,162,000 or $0.31 per basic and diluted share for the same period in 2013. Loss from operations was $19,894,000 against $23,444,000 for the same period a year ago. There were no revenues recognized in the fourth quarter of 2014 and 2013. For the nine months, the company reported a net loss of $86,161,000 or $0.87 per basic and diluted share compared to $90,192,000 or $1.27 per basic and diluted share for the same period in 2013. Loss from operations was $83,951,000 against $87,559,000 for the same period a year ago. There were no revenues recognized for either the year ended December 31, 2014 or for the same period in 2013. The Company expects its cash resources of approximately $97.7 million at December 31, 2014 will be sufficient to fund operations at least through the end of 2015. This estimate assumes no additional funding from new partnership agreements, equity financings or further sales under its ATM. The timing and nature of certain activities contemplated for 2015 will be conducted subject to the availability of sufficient financial resources.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
YDO:GR €2.14 EUR +0.005

YDO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for YDO.
View Industry Companies
 

Industry Analysis

YDO

Industry Average

Valuation YDO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNTA PHARMACEUTICALS CORP, please visit www.syntapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.